Ishay-Ronen et al. showed that rosiglitazone in combination with the MEK inhibitor trametinib enhanced epithelial differentiation and adipogenesis in vivo and in vitro, thus promoting the conversion of invasive breast cancer cells into adipocytes, and ultimately inhibiting the metastasis of cancer cells. Here, MAP2K7 is linked to breast cancer.